{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:02:23Z","timestamp":1777489343981,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03885-1","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:21:08Z","timestamp":1740802868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors"],"prefix":"10.1007","volume":"74","author":[{"given":"Jianming","family":"Diao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyou","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Qing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youneng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"issue":"10192","key":"3885_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet Lond Engl 394(10192):64\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(19)30956-0","journal-title":"Lancet Lond Engl"},{"key":"3885_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-024-10176-9","author":"ZY Su","year":"2024","unstructured":"Su ZY, Siak PY, Lwin YY, Cheah SC (2024) Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Rev. https:\/\/doi.org\/10.1007\/s10555-024-10176-9","journal-title":"Cancer Metastasis Rev"},{"key":"3885_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/tro.2020.02.01","volume":"4","author":"CW Jen","year":"2020","unstructured":"Jen CW, Tsai YC, Wu JS et al (2020) Prognostic classification for patients with nasopharyngeal carcinoma based on American Joint Committee on cancer staging system T and N categories. Ther Radiol Oncol 4:2. https:\/\/doi.org\/10.21037\/tro.2020.02.01","journal-title":"Ther Radiol Oncol"},{"issue":"8","key":"3885_CR4","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J et al (2021) Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 22(8):1162\u20131174. https:\/\/doi.org\/10.1016\/S1470-2045(21)00302-8","journal-title":"Lancet Oncol"},{"issue":"6","key":"3885_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H et al (2023) Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell 41(6):1061\u20131072. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.014","journal-title":"Cancer Cell"},{"key":"3885_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100617","volume":"31","author":"Y Shi","year":"2022","unstructured":"Shi Y, Qin X, Peng X et al (2022) Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study. Lancet Reg Health West Pac 31:100617. https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100617","journal-title":"Lancet Reg Health West Pac"},{"key":"3885_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705096","volume":"12","author":"A Botticelli","year":"2021","unstructured":"Botticelli A, Cirillo A, Strigari L et al (2021) Anti-PD-1 and Anti-PD-L1 in head and neck cancer: a network meta-analysis. Front Immunol 12:705096. https:\/\/doi.org\/10.3389\/fimmu.2021.705096","journal-title":"Front Immunol"},{"issue":"1","key":"3885_CR8","doi-asserted-by":"publisher","first-page":"11472","DOI":"10.1038\/s41598-019-47910-1","volume":"9","author":"LA De Sousa","year":"2019","unstructured":"De Sousa LA, Battin C, Jutz S et al (2019) Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling. Sci Rep 9(1):11472. https:\/\/doi.org\/10.1038\/s41598-019-47910-1","journal-title":"Sci Rep"},{"issue":"1","key":"3885_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"J Yu","year":"2020","unstructured":"Yu J, Song Y, Tian W (2020) How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol OncolJ Hematol Oncol 13(1):45. https:\/\/doi.org\/10.1186\/s13045-020-00876-4","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"2","key":"3885_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24(2):207\u2013212. https:\/\/doi.org\/10.1016\/j.coi.2011.12.009","journal-title":"Curr Opin Immunol"},{"issue":"20","key":"3885_CR11","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","volume":"72","author":"W Peng","year":"2012","unstructured":"Peng W, Liu C, Xu C et al (2012) PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines. Cancer Res 72(20):5209\u20135218. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1187","journal-title":"Cancer Res"},{"issue":"1","key":"3885_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004034","volume":"10","author":"L Zhou","year":"2022","unstructured":"Zhou L, Zeng Z, Egloff AM et al (2022) Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. J Immunother Cancer 10(1):e004034. https:\/\/doi.org\/10.1136\/jitc-2021-004034","journal-title":"J Immunother Cancer"},{"key":"3885_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.558248","volume":"11","author":"B Araujo","year":"2021","unstructured":"Araujo B, de Lima V, Hansen M, Spanggaard I et al (2021) Immune cell profiling of peripheral blood as signature for response during checkpoint inhibition across cancer types. Front Oncol 11:558248. https:\/\/doi.org\/10.3389\/fonc.2021.558248","journal-title":"Front Oncol"},{"key":"3885_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fimmu.2020.00125","volume":"11","author":"S Ottonello","year":"2020","unstructured":"Ottonello S, Genova C, Cossu I et al (2020) Association between response to nivolumab treatment and peripheral blood lymphocyte subsets in patients with non-small cell lung cancer. Front Immunol 11:125. https:\/\/doi.org\/10.3389\/fimmu.2020.00125","journal-title":"Front Immunol"},{"issue":"5","key":"3885_CR15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-20-2891","volume":"27","author":"HJ Chalfin","year":"2021","unstructured":"Chalfin HJ, Pramparo T, Mortazavi A et al (2021) Circulating tumor cell subtypes and T-cell populations as prognostic biomarkers to combination immunotherapy in patients with metastatic genitourinary cancer. Clin Cancer Res Off J Am Assoc Cancer Res 27(5):1391\u20131398. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2891","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"3885_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12967-020-02285-0","volume":"18","author":"M Capone","year":"2020","unstructured":"Capone M, Fratangelo F, Giannarelli D et al (2020) Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. J Transl Med 18(1):121. https:\/\/doi.org\/10.1186\/s12967-020-02285-0","journal-title":"J Transl Med"},{"issue":"20","key":"3885_CR17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053","journal-title":"JAMA"},{"issue":"2","key":"3885_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/2326-6066.CIR-22-0524","volume":"11","author":"R Maniar","year":"2023","unstructured":"Maniar R, Wang PH, Washburn RS et al (2023) Self-renewing CD8+ T-cell abundance in blood associates with response to immunotherapy. Cancer Immunol Res 11(2):164\u2013170. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0524","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"3885_CR19","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n LJ, Maurer DM, O\u2019Hara MH et al (2022) Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med 28(6):1167\u20131177. https:\/\/doi.org\/10.1038\/s41591-022-01829-9","journal-title":"Nat Med"},{"issue":"4","key":"3885_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2217\/imt-2023-0105","volume":"16","author":"X Liu","year":"2024","unstructured":"Liu X, Liu S, Jiang Z et al (2024) Peripheral B-cell levels predict efficacy and overall survival in advanced melanoma patients under PD-1 immunotherapy. Immunotherapy 16(4):223\u2013234. https:\/\/doi.org\/10.2217\/imt-2023-0105","journal-title":"Immunotherapy"},{"issue":"4","key":"3885_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","volume":"42","author":"MJ Smyth","year":"2005","unstructured":"Smyth MJ, Cretney E, Kelly JM et al (2005) Activation of NK cell cytotoxicity. Mol Immunol 42(4):501\u2013510. https:\/\/doi.org\/10.1016\/j.molimm.2004.07.034","journal-title":"Mol Immunol"},{"issue":"2","key":"3885_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18(2):85\u2013100. https:\/\/doi.org\/10.1038\/s41571-020-0426-7","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"3885_CR23","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M et al (2018) Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest 128(10):4654\u20134668. https:\/\/doi.org\/10.1172\/JCI99317","journal-title":"J Clin Invest"},{"issue":"2","key":"3885_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000334","volume":"8","author":"YQ Wang","year":"2020","unstructured":"Wang YQ, Chen L, Mao YP et al (2020) Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology. J Immunother Cancer 8(2):e000334. https:\/\/doi.org\/10.1136\/jitc-2019-000334","journal-title":"J Immunother Cancer"},{"issue":"11","key":"3885_CR25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","volume":"30","author":"YP Chen","year":"2020","unstructured":"Chen YP, Yin JH, Li WF et al (2020) Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res 30(11):1024\u20131042. https:\/\/doi.org\/10.1038\/s41422-020-0374-x","journal-title":"Cell Res"},{"issue":"5","key":"3885_CR26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","volume":"16","author":"S Sivori","year":"2019","unstructured":"Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L (2019) Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol 16(5):430\u2013441. https:\/\/doi.org\/10.1038\/s41423-019-0206-4","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"3885_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19(3):200\u2013218. https:\/\/doi.org\/10.1038\/s41573-019-0052-1","journal-title":"Nat Rev Drug Discov"}],"updated-by":[{"DOI":"10.1007\/s00262-025-04117-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03885-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03885-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03885-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T07:33:40Z","timestamp":1759131220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03885-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["3885"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03885-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4957934\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-025-04117-w","URL":"https:\/\/doi.org\/10.1007\/s00262-025-04117-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for the collection of human data was obtained from the Institutional Review Board (HX-IRB-AF-12-V4.0) of West China Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Prior to enrollment, all participants provided written informed consent. Registry and the Registration No. of the study\/trial: KL-A167 clinical trial (NCT03848286).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}],"article-number":"129"}}